Greenwich LifeSciencesGLSI
About: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Employees: 6
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
15% more funds holding
Funds holding: 34 [Q2] → 39 (+5) [Q3]
0.69% more ownership
Funds ownership: 8.0% [Q2] → 8.69% (+0.69%) [Q3]
8% less capital invested
Capital invested by funds: $17.8M [Q2] → $16.4M (-$1.36M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 62 / 159 met price target | 207%upside $38 | Buy Reiterated | 11 Feb 2025 |
Financial journalist opinion
Based on 5 articles about GLSI published over the past 30 days









